SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology ...
NextSeq 1000 and 2000 systems are redesigned from the ground up to maximize future proofing, offering sequencing power for high throughput applications. Offering scalability for evolving needs and ...
Now Commercially Available, Both NextSeq 1000 and NextSeq 2000 Sequencers Include Integrated Informatics and Loss-less Compression Technology, Creating an Intuitive User Experience Now commercially ...
Illumina, Inc. is further extending the reach of the NextSeq 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. The P3 flow cell offers 1.1 billion reads in a ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The Bristol Genomics Facility offers next-generation sequencing on the NextSeq 2000, one of the newest high-throughput sequencing instruments made by Illumina. The Illumina NextSeq 2000 is a very ...
The NextSeq 1000 and NextSeq 2000 Systems are thoughtfully designed to enable more insights on your benchtop. With 14 configurations and read lengths from 1 × 50bp to 2 × 300bp, these systems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results